Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 797

TitleReference numberPublishedLast updated
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTA1018
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and overTA1019
Elafibranor for previously treated primary biliary cholangitisTA1016
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1015
Avapritinib for treating advanced systemic mastocytosisTA1012
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuriaTA1010
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemiaTA1013
Belzutifan for treating tumours associated with von Hippel-Lindau diseaseTA1011
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertensionTA1009
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatmentsTA1008
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA1007
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1006
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and overTA1002
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and overTA1003
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusionTA1004
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA1005
Iptacopan for treating paroxysmal nocturnal haemoglobinuriaTA1000
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatmentTA1001
Vibegron for treating symptoms of overactive bladder syndromeTA999
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinomaTA997
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Risankizumab for treating moderately to severely active ulcerative colitisTA998
Relugolix for treating hormone-sensitive prostate cancerTA995

Results per page

  1. 10
  2. 25
  3. 50
  4. All